Autologous CD133+cells augment the effect of portal embolization

作者：Canepa M C^*; Quaretti P; Perotti C; Vercelli A; Rademacher J; Peloso A; Barbieri L; Franchi E; Briani L; Gaspari A; Brugnatelli S; Pedrazzoli P; Dionigi P; Maestri M

来源：Minerva Chirurgica, 2013, 68(2): 163-168.

• Hepatectomy
• Stem cells
• Portal vein
• Embolization, therapeutic

Aim. The standard to treat liver tumors is a resection. When the future liver remnant (FLRV) is below 30% (healthy livers) or 40% (cirrhotic livers or previous chemotherapy), surgery carries the risk of severe complications. Portal vein embolization (PVE) gained a worldwide diffusion as a tool to augment the FLRV. Cell therapies are recent players at the frontiers of medicine. This study presents a clinical experience to evaluate the synergistic effect of combined PVE and autologous CD133+ cells coadministration. %26lt;br%26gt;Methods. Sixteen patients have been enrolled in the study up today. Inclusion criteria were: primary or metastatic liver malignancy with a FLRV%26lt;30% or 40%. A baseline volumetric CT-scan was obtained. CD34+ were mobilized to the blood stream by G-CSF administration and collected by immunomagnetic separation. Simultaneously with PVE, cells were administered to the non occluded liver segments. Follow-up CT scans were taken at 30th post treatment day. %26lt;br%26gt;Results. The patients (N.=6) showed an increased volume gain (Mann-Whitney test P%26lt;0.001, two sided) compared to a set of cases whose treatment was PVE only (N.=10). %26lt;br%26gt;Discussion. The use of autologous stem cells as an augmenter of liver regeneration has a clinical potential to improve the resectability of liver tumors.

• 出版日期2013-4